Roche, Genentech sign license deal with Kiniksa for vixarelimab

Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.